Headlands Technologies LLC acquired a new stake in Chemed Co. (NYSE:CHE - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 434 shares of the company's stock, valued at approximately $230,000.
A number of other large investors also recently bought and sold shares of the company. UMB Bank n.a. increased its stake in Chemed by 300.0% during the fourth quarter. UMB Bank n.a. now owns 52 shares of the company's stock worth $28,000 after acquiring an additional 39 shares during the last quarter. Atala Financial Inc acquired a new position in shares of Chemed in the 4th quarter valued at approximately $29,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Chemed by 64.7% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 56 shares of the company's stock worth $30,000 after purchasing an additional 22 shares during the last quarter. Trust Co. of Vermont acquired a new position in Chemed in the fourth quarter worth $34,000. Finally, Tortoise Investment Management LLC raised its holdings in shares of Chemed by 77.3% during the fourth quarter. Tortoise Investment Management LLC now owns 78 shares of the company's stock worth $41,000 after purchasing an additional 34 shares during the period. Hedge funds and other institutional investors own 95.85% of the company's stock.
Chemed Price Performance
Shares of NYSE CHE traded down $5.96 during trading hours on Thursday, hitting $582.09. 27,693 shares of the company's stock were exchanged, compared to its average volume of 96,489. The company's 50-day moving average price is $581.75 and its 200-day moving average price is $567.98. Chemed Co. has a 1-year low of $512.12 and a 1-year high of $627.12. The stock has a market capitalization of $8.52 billion, a price-to-earnings ratio of 29.41, a PEG ratio of 2.15 and a beta of 0.49.
Chemed Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Monday, February 24th were paid a $0.50 dividend. The ex-dividend date was Monday, February 24th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.34%. Chemed's payout ratio is 10.05%.
Insider Buying and Selling
In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $593.67, for a total value of $1,187,340.00. Following the completion of the transaction, the chief executive officer now owns 102,679 shares of the company's stock, valued at $60,957,441.93. This represents a 1.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.32% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Several research firms recently commented on CHE. Royal Bank of Canada raised their target price on Chemed from $633.00 to $667.00 and gave the company an "outperform" rating in a research report on Friday, March 14th. StockNews.com upgraded shares of Chemed from a "hold" rating to a "buy" rating in a report on Friday, March 7th.
Check Out Our Latest Analysis on CHE
Chemed Profile
(
Free Report)
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Recommended Stories

Before you consider Chemed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.
While Chemed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.